In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose ...

The safety and efficacy of dostarlimab plus chemotherapy in patients with advanced endometrial cancer were confirmed by ...

GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK).

In what can be termed a never-seen-before medical miracle, a small group of people with colorectal cancer achieved 100% ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal ...

The drugmaker remains convinced of the potential of the drug, however, and has just reported results of a trial comparing Jemperli (dostarlimab ... non-small cell lung cancer (NSCLC) that has ...

Lurie Comprehensive Cancer Center at Northwestern University will participate in a clinical trial testing LIXTE's drug LB-100 in combination with GSK's immunotherapy Dostarlimab for treating ...

plan to file an Investigational New Drug (IND) application in 2026 -- "We continue to advance our Claudin 18.2 ADC program, EO-3021, for the treatment of advanced gastric/GEJ cancer in the earlier ...

In March 2025, Coordination Pharmaceuticals Inc. announced a phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or ...